News Releases

News Releases

SALT LAKE CITY --(BUSINESS WIRE)--Jun. 11, 2018-- Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that they will be hosting a booth at the

CoPrimers™ used in proof of concept evaluation SALT LAKE CITY --(BUSINESS WIRE)--Jun. 1, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is

SALT LAKE CITY --(BUSINESS WIRE)--Apr. 16, 2018-- Co-Diagnostics , Inc. (Nasdaq: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced today that it will discuss the Company’s strategic direction and recent corporate

CODX updates on initial six months as a public company SALT LAKE CITY --(BUSINESS WIRE)--Apr. 5, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the filing of its initial Annual

Project moving forward on schedule, with production to begin in Q3 2018 SALT LAKE CITY --(BUSINESS WIRE)--Mar. 22, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the

SALT LAKE CITY --(BUSINESS WIRE)--Feb. 28, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities

Shipment includes 10,000 tests to be sold as Research Use Only by Joint Venture SALT LAKE CITY --(BUSINESS WIRE)--Feb. 21, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today

Program received enthusiastically by regional Ministries of Health SALT LAKE CITY --(BUSINESS WIRE)--Jan. 30, 2018-- Co-Diagnostics , Inc. (NASDAQ: CODX) , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today the completion of

Pagination

About Co-Diagnostics

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our molecular diagnostics development platform is marketed under the brand name Co-Dx™. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.